Physician profile
Albert Samost
NPI 1609339787
$1,329.28
in general payments reported to CMS, 2019-2025
14 companies · $533 in 2025
The $533 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $218 · 2024: $579 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,329.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $267.61 | 2024-2025 | |
| Novo Nordisk INC | $198.37 | 2024-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $128.56 | 2023-2025 | Airsupra, Lokelma, Farxiga |
| Amgen INC. | $126.02 | 2024-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $115.80 | 2024-2025 | |
| Incyte Corporation | $101.10 | 2023 | Jakafi |
| Exact Sciences Corporation | $97.53 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $73.10 | 2024-2025 | Zepbound, Mounjaro |
| Gilead Sciences, INC. | $65.19 | 2023 | |
| Glaxosmithkline, LLC. | $50.23 | 2024-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Astellas Pharma US INC | $34.64 | 2024 | Veozah |
| Inspire Medical Systems, INC. | $33.88 | 2025 | Inspire |
| Tms Neurohealth Centers INC. | $20.39 | 2025 | Tms Neurohealth Centers INC. |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.86 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Samost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.